drugset / Trial / NCT05927415

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

NCT05927415

Phase 1 Completed 33 enrolled argenx
Non-randomizedParallel-groupOpen-labelOther

Summary

A study to test how kidney problems influence the blood concentrations of efgartigimod

Timeline

Start
2023-07-17
Primary completion
2024-06-12
Completion
2024-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic 10 mg/kg Intravenous